On May 15, the cloud signing and unveiling ceremony for the Sichuan University-University of Oxford Huaxi Joint Center for Gastrointestinal Cancer was held in Yiji Building, West China Hospital.
Professor Louise Richardson,vice-chancellor of the University of Oxford;Professor Nick Brown, dean ofLinacre College; Professor Mark Middleton, head of the Department of Oncology, Professor David Kerr; senior associate researcher of Shijie Tsai and Michael Youdell of the Cancer Center;ProfessorYanrong Li, president of Sichuan University and academician of the Chinese Academy of Sciences; Professor Shijing Yan, vice president of SCU; Professor Weimin Li, dean of West China School of Medicine (West China Hospital) attended the ceremony.
On behalf of SCU, Yanrong Li gave congratulations on the establishment of the center and thanked the experts from both sides for their great support. He said that Oxford University is one of the world's oldest and most influential institutions of higher learning, especially in the field of life science. As the first scientific research and cooperation platform jointly built by Oxford University and a university in Western China in the field of medicine, the Huaxi Joint Center will be a place for scholars from the two universities and their global counterparts to collaborate in scientific research, student training, holding international academic conferences, and publishing high-level papers, etc. In particular, the scholars can concentrate on major life and health issues, such as cancer treatment, tumor marker development, total neoadjuvant therapy and imaging so as to provide better scientific treatment programs for the benefit of human health. Finally, he hoped that this project will serve as a new starting point to promote a deeper, more comprehensive and closer cooperative relationship between the two universities, and that professors from the two universities will actively participate in the cooperation and contribute to the friendship and development of the two universities.
On behalf of Oxford University, Professor Richardson offered congratulations on the founding of the center and thanked SCU for its support. She said that the Huaxi Joint Center will provide comprehensive cancer treatment plans for gastrointestinal cancer based on high-quality basic, translational and clinical cancer research to benefit human health. The establishment of the center will promote the academic exchange, scientific cooperation and talent training between the two sides, and contribute to cancer treatment. Oxford University and Sichuan University share a common vision of progress and academic atmosphere. We believe that the cooperation between the two world's leading academic institutions will promote the friendship between the two countries and safeguard the health of the two peoples as well as all mankind.
Weimin Li and Mark Middleton respectively introduced the basic situation of West China School of Medicine (Huaxi Hospital) and the Department of Oncology of Oxford University, reviewed the cooperation foundation of the two sides in scientific research, teacher exchange, and joint training of students. They then looked forward to the construction and future development of the Huaxi Joint Center.
Louise Richardson, the vice-chancellor and President Yanrong Li signed the “Agreement of Sichuan University-University of Oxford Huaxi Joint Center for Gastrointestinal Cancer”. In front of the distinguished guests in attendance, President Yanrong Li, President Weimin Li of WCH and Professor Mark Middleton opened the center.
The Sichuan University-University of Oxford Huaxi Joint Center for Gastrointestinal Cancer is the first scientific research and cooperation platform jointly built by Oxford University and a university in Western China in the field of medicine. Here, scholars from the two universities and their global counterparts will collaborate in personnel training, scientific research, diagnosis and treatment. In particular, they will research on major life and health issues, provide early diagnosis and treatment of related diseases, and improve the survival rate of patients with more scientific treatment programs so as to benefit human health.
